

GREETINGS FROM THE EDITOR-IN-CHIEF

If you are like most healthcare professionals your email, Blackberry, cell phone, pager and office messages all place demands on your time, making it difficult to keep up with journals. At Epilepsy.com/Professionals, we strive to bring you the latest information that is pertinent to you and your care of patients with epilepsy.

This month we direct your attention to the latest FDA Medication Error Report as well as Dr. W Curt La France's commentary on the use of serum prolactin in diagnosing epilepsy. We also are excited to feature two new CME courses on pediatric and geriatric epilepsy.

In the next couple months we will bring you many of the highlights of the upcoming American Epilepsy Society meeting. Early indications are there will be many exciting developments announced at the meeting!

Steven C. Schachter, MD, Editor-in-Chief
Professor of Neurology, Harvard Medical School, Director of Research
Department of Neurology, Beth Israel Deaconess Medical Center

MARK YOUR CALENDAR

Upcoming epilepsy-related conferences, symposiums and events include:

November 5-13, 2005

World Congress of Neurology 2005 Sidney, Australia

November 12-16, 2005

Society for Neuroscience 35th Annual Meeting
Washington, DC

December 2-6, 2005

American Epilepsy Society 59th Annual Meeting,
Washington, DC

STAY TUNED

- News from AES

THE USE OF SERUM PROLACTIN IN DIAGNOSING EPILEPTIC SEIZURES

Dr. W Curt La France, Jr., Brown Medical School, a leading expert in non-epileptic seizures, dissects the latest report published by the American Academy of Neurology addressing the reliability and usefulness of serum prolactin in differentiating epileptic from nonepileptic seizures. [Read more.](#)



NEW CONTINUING MEDICAL EDUCATION COURSES

Epilepsy.com is committed to providing physicians with current, state-of-the-art Continuing Medical Education (CME). That's why we are excited to announce our newest CME courses on pediatric and geriatric epilepsy. [Read more.](#)

HEALTH WATCH: FDA RELEASES NEW MEDICATION ERROR REPORT

The Food and Drug Administration (FDA), Ortho-McNeil Neurologics Inc. and AstraZeneca has issued a letter to healthcare professionals alerting them of recent reports of medication errors involving Toprol-XL (a beta blocker used to treat hypertension, angina pectoris and heart failure) and Topamax (used to treat epilepsy and migraines). There have also been reports of medication errors involving Toprol-XL and Tegretol or Tegretol-XR, used to treat complex partial seizures, generalized tonic-clonic seizures, and trigeminal neuralgia.

View the http://www.fda.gov/medwatch/safety/2005/toprol_dhcp.pdf PDF document for more details

ABOUT THE EPILEPSY THERAPY DEVELOPMENT PROJECT

The **Epilepsy Therapy Development Project** is a 501 (c) (3) not-for-profit corporation. The organization was founded by three fathers of young children with epilepsy, along with their children's doctor, a leading researcher and clinician in the field of epilepsy. Our mission is to advance new treatments for people living with epilepsy.

The Epilepsy Therapy Development Project is also the sponsor of epilepsy.com and epilepsy.com/professionals. We are working to build epilepsy.com/professionals into the most comprehensive source of information, tools and interchange available online for patients, practicing neurologists, and for the research and therapy development community.

To learn more about our programs, please visit [The Epilepsy Therapy Development Project](http://TheEpilepsyTherapyDevelopmentProject.com). You can help us reach our goals and continue support of epilepsy.com with your [donations](http://donations.com).

